Publication list - Publika - Scientific publications from Oslo University Hospital

Publications by Anne Hansen Ree

142 publications found

Original articles

Mecinaj A, Gulati G, Ree AH, Gravdehaug B, Røsjø H, Steine K, Wisløff T, Geisler J, Omland T, Heck SL (2024)
Impact of the ESC Cardio-Oncology Guidelines Biomarker Criteria on Incidence of Cancer Therapy-Related Cardiac Dysfunction
JACC CardioOncol, 6 (1), 83-95
DOI 10.1016/j.jaccao.2023.10.008, PubMed 38510299

Knuth F, Tohidinezhad F, Winter RM, Bakke KM, Negård A, Holmedal SH, Ree AH, Meltzer S, Traverso A, Redalen KR (2024)
Quantitative MRI-based radiomics analysis identifies blood flow feature associated to overall survival for rectal cancer patients
Sci Rep, 14 (1), 258
DOI 10.1038/s41598-023-50966-9, PubMed 38167665

Bjørnetrø T, Bousquet PA, Redalen KR, Trøseid AS, Lüders T, Stang E, Sanabria AM, Johansen C, Fuglestad AJ, Kersten C, Meltzer S, Ree AH (2023)
Next-generation sequencing reveals mitogenome diversity in plasma extracellular vesicles from colorectal cancer patients
BMC Cancer, 23 (1), 650
DOI 10.1186/s12885-023-11092-x, PubMed 37438741

Larsen TL, Svalastoga M, Brekke J, Enden T, Frøen H, Garresori H, Jacobsen EM, Paulsen PQ, Porojnicu AC, Ree AH, Torfoss D, Velle EO, Wik HS, Ghanima W, Sandset PM, Dahm AEA (2023)
Arterial events in cancer patients treated with apixaban for venous thrombosis
Thromb Res, 228, 128-133
DOI 10.1016/j.thromres.2023.05.017, PubMed 37327527

Buckley CE, Yin X, Meltzer S, Ree AH, Redalen KR, Brennan L, O'Sullivan J, Lynam-Lennon N (2023)
Energy Metabolism Is Altered in Radioresistant Rectal Cancer
Int J Mol Sci, 24 (8)
DOI 10.3390/ijms24087082, PubMed 37108244

Nygaard V, Ree AH, Dagenborg VJ, Børresen-Dale AL, Edwin B, Fretland ÅA, Grzyb K, Haugen MH, Mælandsmo GM, Flatmark K (2023)
A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases
Cancer Res Commun, 3 (2), 235-244
DOI 10.1158/2767-9764.CRC-22-0295, PubMed 36968142

Bakke KM, Meltzer S, Grøvik E, Negård A, Holmedal SH, Mikalsen LTG, Færden AE, Lyckander LG, Julbø FMI, Bjørnerud A, Gjesdal KI, Ree AH, Redalen KR (2023)
Imaging the tumour microenvironment in rectal cancer: Decline in tumour blood flow during radiotherapy predicts good outcome
Phys Imaging Radiat Oncol, 25, 100417
DOI 10.1016/j.phro.2023.100417, PubMed 36718357

Høye E, Dagenborg VJ, Torgunrud A, Lund-Andersen C, Fretland ÅA, Lorenz S, Edwin B, Hovig E, Fromm B, Inderberg EM, Greiff V, Ree AH, Flatmark K (2022)
T cell receptor repertoire sequencing reveals chemotherapy-driven clonal expansion in colorectal liver metastases
Gigascience, 12
DOI 10.1093/gigascience/giad032, PubMed 37161965

Meltzer S, Negård A, Bakke KM, Hamre HM, Kersten C, Hofsli E, Guren MG, Sorbye H, Flatmark K, Ree AH (2022)
Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer
Br J Cancer, 127 (12), 2227-2233
DOI 10.1038/s41416-022-02004-0, PubMed 36229579

Fuglestad AJ, Meltzer S, Ree AH, McMillan DC, Park JH, Kersten C (2022)
The clinical value of C-reactive protein and its association with tumour location in patients undergoing curative surgery for colorectal cancer - a ScotScan collaborative study
Acta Oncol, 61 (10), 1248-1255
DOI 10.1080/0284186X.2022.2117572, PubMed 36068730

Ree AH, Mælandsmo GM, Flatmark K, Russnes HG, Gómez Castañeda M, Aas E (2022)
Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer - the MetAction precision medicine study
Acta Oncol, 61 (8), 955-962
DOI 10.1080/0284186X.2022.2098053, PubMed 35943168

Malenge MM, Maaland AF, Repetto-Llamazares A, Middleton B, Nijland M, Visser L, Patzke S, Heyerdahl H, Kolstad A, Stokke T, Ree AH, Dahle J (2022)
Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin's lymphoma in vitro
PLoS One, 17 (4), e0267543
DOI 10.1371/journal.pone.0267543, PubMed 35486574

Ambrosini M, Del Re M, Manca P, Hendifar A, Drilon A, Harada G, Ree AH, Klempner S, Mælandsmo GM, Flatmark K, Russnes HG, Cleary JM, Singh H, Sottotetti E, Martinetti A, Randon G, Sartore-Bianchi A, Capone I, Milione M, Di Bartolomeo M, Pietrantonio F (2022)
ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series
JCO Precis Oncol, 6 (1), e2200015
DOI 10.1200/PO.22.00015, PubMed 35476549

Larsen TL, Garresori H, Brekke J, Enden T, Frøen H, Jacobsen EM, Quist-Paulsen P, Porojnicu AC, Ree AH, Torfoss D, Osvik Velle E, Skuterud Wik H, Ghanima W, Sandset PM, Dahm AEA (2022)
Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up
J Thromb Haemost, 20 (5), 1166-1181
DOI 10.1111/jth.15666, PubMed 35114046

Bousquet PA, Meltzer S, Fuglestad AJ, Lüders T, Esbensen Y, Juul HV, Johansen C, Lyckander LG, Bjørnetrø T, Inderberg EM, Kersten C, Redalen KR, Ree AH (2021)
The mitochondrial DNA constitution shaping T-cell immunity in patients with rectal cancer at high risk of metastatic progression
Clin Transl Oncol, 24 (6), 1157-1167
DOI 10.1007/s12094-021-02756-w, PubMed 34961902

Knuth F, Adde IA, Huynh BN, Groendahl AR, Winter RM, Negård A, Holmedal SH, Meltzer S, Ree AH, Flatmark K, Dueland S, Hole KH, Seierstad T, Redalen KR, Futsaether CM (2021)
MRI-based automatic segmentation of rectal cancer using 2D U-Net on two independent cohorts
Acta Oncol, 61 (2), 255-263
DOI 10.1080/0284186X.2021.2013530, PubMed 34918621

Dagenborg VJ, Marshall SE, Grzyb K, Fretland ÅA, Lund-Iversen M, Mælandsmo GM, Ree AH, Edwin B, Yaqub S, Flatmark K (2021)
Low Concordance Between T-Cell Densities in Matched Primary Tumors and Liver Metastases in Microsatellite Stable Colorectal Cancer
Front Oncol, 11, 671629
DOI 10.3389/fonc.2021.671629, PubMed 34178659

Heck SL, Mecinaj A, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, Røsjø H, Steine K, Geisler J, Gulati G, Omland T (2021)
Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol
Circulation, 143 (25), 2431-2440
DOI 10.1161/CIRCULATIONAHA.121.054698, PubMed 33993702

Abrahamsson H, Meltzer S, Hagen VN, Johansen C, Bousquet PA, Redalen KR, Ree AH (2021)
Sex disparities in vitamin D status and the impact on systemic inflammation and survival in rectal cancer
BMC Cancer, 21 (1), 535
DOI 10.1186/s12885-021-08260-2, PubMed 33975557

Meltzer S, Torgunrud A, Abrahamsson H, Solbakken AM, Flatmark K, Dueland S, Bakke KM, Bousquet PA, Negård A, Johansen C, Lyckander LG, Larsen FO, Schou JV, Redalen KR, Ree AH (2021)
The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer
Br J Cancer, 125 (2), 240-246
DOI 10.1038/s41416-021-01377-y, PubMed 33837301

Bjørnetrø T, Steffensen LA, Vestad B, Brusletto BS, Olstad OK, Trøseid AM, Aass HCD, Haug KBF, Llorente A, Bøe SO, Lång A, Samiappan R, Redalen KR, Øvstebø R, Ree AH (2021)
Uptake of circulating extracellular vesicles from rectal cancer patients and differential responses by human monocyte cultures
FEBS Open Bio, 11 (3), 724-740
DOI 10.1002/2211-5463.13098, PubMed 33512765

Bakke KM, Meltzer S, Grøvik E, Negård A, Holmedal SH, Gjesdal KI, Bjørnerud A, Ree AH, Redalen KR (2020)
Sex Differences and Tumor Blood Flow from Dynamic Susceptibility Contrast MRI Are Associated with Treatment Response after Chemoradiation and Long-term Survival in Rectal Cancer
Radiology, 297 (2), 352-360
DOI 10.1148/radiol.2020200287, PubMed 32870132

Hannevik TL, Brekke J, Enden T, Frøen H, Garresori H, Jacobsen EM, Paulsen PQ, Porojnicu AC, Ree AH, Torfoss D, Velle EO, Wik HS, Ghanima W, Sandset PM, Dahm AEA (2020)
Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism
Thromb Res, 196, 238-244
DOI 10.1016/j.thromres.2020.08.042, PubMed 32919178

Malenge MM, Patzke S, Ree AH, Stokke T, Ceuppens P, Middleton B, Dahle J, Repetto-Llamazares AHV (2020)
¹⁷⁷Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma
J Nucl Med, 61 (10), 1468-1475
DOI 10.2967/jnumed.119.237230, PubMed 32245896

Ree AH, Nygaard V, Boye K, Heinrich D, Dueland S, Bergheim IR, Johansen C, Beiske K, Negård A, Lund-Iversen M, Nygaard V, Hovig E, Nakken S, Nasser S, Julsrud L, Reisse CH, Ruud EA, Kristensen VN, Flørenes VA, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Russnes HG, Mælandsmo GM, Flatmark K (2020)
Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study
Acta Oncol, 59 (7), 733-740
DOI 10.1080/0284186X.2020.1742377, PubMed 32208873

Dagenborg VJ, Marshall SE, Yaqub S, Grzyb K, Boye K, Lund-Iversen M, Høye E, Berstad AE, Fretland ÅA, Edwin B, Ree AH, Flatmark K (2020)
Neoadjuvant chemotherapy is associated with a transient increase of intratumoral T-cell density in microsatellite stable colorectal liver metastases
Cancer Biol Ther, 21 (5), 432-440
DOI 10.1080/15384047.2020.1721252, PubMed 32098573

Abrahamsson H, Jensen BV, Berven LL, Nielsen DL, Šaltytė Benth J, Johansen JS, Larsen FO, Johansen JS, Ree AH (2020)
Antitumour immunity invoked by hepatic arterial infusion of first-line oxaliplatin predicts durable colorectal cancer control after liver metastasis ablation: 8-12 years of follow-up
Int J Cancer, 146 (7), 2019-2026
DOI 10.1002/ijc.32847, PubMed 31872440

Bains SJ, Abrahamsson H, Flatmark K, Dueland S, Hole KH, Seierstad T, Redalen KR, Meltzer S, Ree AH (2019)
Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer
Cancer Immunol Immunother, 69 (3), 355-364
DOI 10.1007/s00262-019-02458-x, PubMed 31893287

Meltzer S, Bakke KM, Rød KL, Negård A, Flatmark K, Solbakken AM, Kristensen AT, Fuglestad AJ, Kersten C, Dueland S, Seierstad T, Hole KH, Lyckander LG, Larsen FO, Schou JV, Patrick Brown D, Abrahamsson H, Redalen KR, Ree AH (2019)
Sex-related differences in primary metastatic site in rectal cancer; associated with hemodynamic factors?
Clin Transl Radiat Oncol, 21, 5-10
DOI 10.1016/j.ctro.2019.11.006, PubMed 31872084

Meltzer S, Bjørnetrø T, Lyckander LG, Flatmark K, Dueland S, Samiappan R, Johansen C, Kalanxhi E, Ree AH, Redalen KR (2019)
Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer
Transl Oncol, 12 (8), 1038-1044
DOI 10.1016/j.tranon.2019.04.014, PubMed 31146167

Abrahamsson H, Porojnicu AC, Lindstrøm JC, Dueland S, Flatmark K, Hole KH, Seierstad T, Moan J, Redalen KR, Meltzer S, Ree AH (2019)
High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer
BMC Cancer, 19 (1), 488
DOI 10.1186/s12885-019-5724-z, PubMed 31122213

Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM (2019)
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases
Transl Oncol, 12 (7), 951-958
DOI 10.1016/j.tranon.2019.04.001, PubMed 31096111

Bakke KM, Grøvik E, Meltzer S, Negård A, Holmedal SH, Mikalsen LTG, Lyckander LG, Ree AH, Gjesdal KI, Redalen KR, Bjørnerud A (2019)
Comparison of Intravoxel incoherent motion imaging and multiecho dynamic contrast-based MRI in rectal cancer
J Magn Reson Imaging, 50 (4), 1114-1124
DOI 10.1002/jmri.26740, PubMed 30945379

Ree AH, Nygaard V, Russnes HG, Heinrich D, Nygaard V, Johansen C, Bergheim IR, Hovig E, Beiske K, Negård A, Børresen-Dale AL, Flatmark K, Mælandsmo GM (2019)
Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain
Cancer Immunol Res, 7 (5), 701-706
DOI 10.1158/2326-6066.CIR-18-0777, PubMed 30804006

Bjørnetrø T, Redalen KR, Meltzer S, Thusyanthan NS, Samiappan R, Jegerschöld C, Handeland KR, Ree AH (2019)
An experimental strategy unveiling exosomal microRNAs 486-5p, 181a-5p and 30d-5p from hypoxic tumour cells as circulating indicators of high-risk rectal cancer
J Extracell Vesicles, 8 (1), 1567219
DOI 10.1080/20013078.2019.1567219, PubMed 30728923

Bousquet PA, Meltzer S, Sønstevold L, Esbensen Y, Dueland S, Flatmark K, Sitter B, Bathen TF, Seierstad T, Redalen KR, Eide L, Ree AH (2018)
Markers of Mitochondrial Metabolism in Tumor Hypoxia, Systemic Inflammation, and Adverse Outcome of Rectal Cancer
Transl Oncol, 12 (1), 76-83
DOI 10.1016/j.tranon.2018.09.010, PubMed 30273860

Boysen AK, Sørensen BS, Lefevre AC, Abrantes R, Johansen JS, Jensen BV, Schou JV, Larsen FO, Nielsen D, Taflin H, Gustavson B, Wettergren Y, Sorensen BS, Ree AH, Dueland S, Pallisgaard N, Spindler KL (2018)
Methodological development and biological observations of cell free DNA with a simple direct fluorescent assay in colorectal cancer
Clin Chim Acta, 487, 107-111
DOI 10.1016/j.cca.2018.09.029, PubMed 30240586

Heck SL, Gulati G, Hoffmann P, von Knobelsdorff-Brenkenhoff F, Storås TH, Ree AH, Gravdehaug B, Røsjø H, Steine K, Geisler J, Schulz-Menger J, Omland T (2018)
Effect of candesartan and metoprolol on myocardial tissue composition during anthracycline treatment: the PRADA trial
Eur Heart J Cardiovasc Imaging, 19 (5), 544-552
DOI 10.1093/ehjci/jex159, PubMed 29106497

Kalanxhi E, Meltzer S, Schou JV, Larsen FO, Dueland S, Flatmark K, Jensen BV, Hole KH, Seierstad T, Redalen KR, Nielsen DL, Ree AH (2018)
Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer
Br J Cancer, 118 (10), 1322-1328
DOI 10.1038/s41416-018-0085-y, PubMed 29695770

Gopinathan U, Redalen KR, Trøseid AM, Kierulf P, Brandtzaeg P, Ree AH, Berg JP, Øvstebø R (2018)
Large-scale reduction of tyrosine kinase activities in human monocytes stimulated in vitro with N. meningitidis
PLoS One, 13 (1), e0181912
DOI 10.1371/journal.pone.0181912, PubMed 29357362

Gulati G, Heck SL, Røsjø H, Ree AH, Hoffmann P, Hagve TA, Norseth J, Gravdehaug B, Steine K, Geisler J, Omland T (2017)
Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study
J Am Heart Assoc, 6 (11)
DOI 10.1161/JAHA.117.006513, PubMed 29118031

Østrup O, Dagenborg VJ, Rødland EA, Skarpeteig V, Silwal-Pandit L, Grzyb K, Berstad AE, Fretland ÅA, Mælandsmo GM, Børresen-Dale AL, Ree AH, Edwin B, Nygaard V, Flatmark K (2017)
Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases
Oncotarget, 8 (44), 76290-76304
DOI 10.18632/oncotarget.19350, PubMed 29100312

Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA et al. (2017)
Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
ESMO Open, 2 (2), e000158
DOI 10.1136/esmoopen-2017-000158, PubMed 28761742

Bakke KM, Hole KH, Dueland S, Grøholt KK, Flatmark K, Ree AH, Seierstad T, Redalen KR (2017)
Diffusion-weighted magnetic resonance imaging of rectal cancer: tumour volume and perfusion fraction predict chemoradiotherapy response and survival
Acta Oncol, 56 (6), 813-818
DOI 10.1080/0284186X.2017.1287951, PubMed 28464745

Grøvik E, Redalen KR, Storås TH, Negård A, Holmedal SH, Ree AH, Meltzer S, Bjørnerud A, Gjesdal KI (2016)
Dynamic multi-echo DCE- and DSC-MRI in rectal cancer: Low primary tumor K^trans and ΔR2* peak are significantly associated with lymph node metastasis
J Magn Reson Imaging, 46 (1), 194-206
DOI 10.1002/jmri.25566, PubMed 28001320

Jonsson M, Ragnum HB, Julin CH, Yeramian A, Clancy T, Frikstad KM, Seierstad T, Stokke T, Matias-Guiu X, Ree AH, Flatmark K, Lyng H (2016)
Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition
Br J Cancer, 115 (8), 929-939
DOI 10.1038/bjc.2016.278, PubMed 27599042

Kalanxhi E, Risberg K, Barua IS, Dueland S, Waagene S, Andersen SN, Pettersen SJ, Lindvall JM, Redalen KR, Flatmark K, Ree AH (2016)
Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy
Cancer Res Treat, 49 (2), 374-386
DOI 10.4143/crt.2016.080, PubMed 27488871

Risberg K, Redalen KR, Sønstevold L, Bjørnetrø T, Sølvernes J, Ree AH (2016)
Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells
BMC Cancer, 16, 531
DOI 10.1186/s12885-016-2600-y, PubMed 27461218

Kalanxhi E, Hektoen HH, Meltzer S, Dueland S, Flatmark K, Ree AH (2016)
Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening
BMC Cancer, 16, 536
DOI 10.1186/s12885-016-2601-x, PubMed 27461255

Meltzer S, Kalanxhi E, Hektoen HH, Dueland S, Flatmark K, Redalen KR, Ree AH (2016)
Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer
Oncotarget, 7 (23), 34907-17
DOI 10.18632/oncotarget.8995, PubMed 27145458

Flatmark K, Saelen MG, Hole KH, Abrahamsen TW, Fleten KG, Hektoen HH, Redalen KR, Seierstad T, Dueland S, Ree AH (2016)
Individual tumor volume responses to short-course oxaliplatin-containing induction chemotherapy in locally advanced rectal cancer - Targeting the tumor for radiation sensitivity?
Radiother Oncol, 119 (3), 505-11
DOI 10.1016/j.radonc.2016.02.020, PubMed 26968754

Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, von Knobelsdorff-Brenkenhoff F, Bratland Å, Storås TH, Hagve TA, Røsjø H, Steine K, Geisler J, Omland T (2016)
Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol
Eur Heart J, 37 (21), 1671-80
DOI 10.1093/eurheartj/ehw022, PubMed 26903532

Dueland S, Ree AH, Grøholt KK, Saelen MG, Folkvord S, Hole KH, Seierstad T, Larsen SG, Giercksky KE, Wiig JN, Boye K, Flatmark K (2016)
Oxaliplatin-containing Preoperative Therapy in Locally Advanced Rectal Cancer: Local Response, Toxicity and Long-term Outcome
Clin Oncol (R Coll Radiol), 28 (8), 532-9
DOI 10.1016/j.clon.2016.01.014, PubMed 26888115

Redalen KR, Sitter B, Bathen TF, Grøholt KK, Hole KH, Dueland S, Flatmark K, Ree AH, Seierstad T (2015)
High tumor glycine concentration is an adverse prognostic factor in locally advanced rectal cancer
Radiother Oncol, 118 (2), 393-8
DOI 10.1016/j.radonc.2015.11.031, PubMed 26705680

Hektoen HH, Ree AH, Redalen KR, Flatmark K (2015)
Sulfamate inhibitor S4 influences carbonic anhydrase IX ectodomain shedding in colorectal carcinoma cells
J Enzyme Inhib Med Chem, 31 (5), 779-86
DOI 10.3109/14756366.2015.1069286, PubMed 26244271

Hektoen HH, Flatmark K, Andersson Y, Dueland S, Redalen KR, Ree AH (2015)
Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer
BMC Cancer, 15, 543
DOI 10.1186/s12885-015-1557-6, PubMed 26205955

Seierstad T, Hole KH, Grøholt KK, Dueland S, Ree AH, Flatmark K, Redalen KR (2015)
MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancer
Br J Radiol, 88 (1051), 20150097
DOI 10.1259/bjr.20150097, PubMed 25899892

Ree AH, Saelen MG, Kalanxhi E, Østensen IH, Schee K, Røe K, Abrahamsen TW, Dueland S, Flatmark K (2014)
Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy
PLoS One, 9 (2), e89750
DOI 10.1371/journal.pone.0089750, PubMed 24587009

Ragnum HB, Røe K, Holm R, Vlatkovic L, Nesland JM, Aarnes EK, Ree AH, Flatmark K, Seierstad T, Lilleby W, Lyng H (2013)
Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer
Int J Radiat Oncol Biol Phys, 87 (4), 753-60
DOI 10.1016/j.ijrobp.2013.07.023, PubMed 24035332

Tahiri A, Røe K, Ree AH, de Wijn R, Risberg K, Busch C, Lønning PE, Kristensen V, Geisler J (2013)
Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma
PLoS One, 8 (8), e72692
DOI 10.1371/journal.pone.0072692, PubMed 24023633

Hole KH, Larsen SG, Grøholt KK, Giercksky KE, Ree AH (2013)
Magnetic resonance-guided histopathology for improved accuracy of tumor response evaluation of neoadjuvant treatment in organ-infiltrating rectal cancer
Radiother Oncol, 107 (2), 178-83
DOI 10.1016/j.radonc.2013.03.017, PubMed 23602370

Røe K, Bratland Å, Vlatkovic L, Ragnum HB, Saelen MG, Olsen DR, Marignol L, Ree AH (2013)
Hypoxic tumor kinase signaling mediated by STAT5A in development of castration-resistant prostate cancer
PLoS One, 8 (5), e63723
DOI 10.1371/journal.pone.0063723, PubMed 23675504

Saelen MG, Ree AH, Kristian A, Fleten KG, Furre T, Hektoen HH, Flatmark K (2012)
Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma
Radiat Oncol, 7, 165
DOI 10.1186/1748-717X-7-165, PubMed 23017053

Røe K, Mikalsen LT, van der Kogel AJ, Bussink J, Lyng H, Ree AH, Marignol L, Olsen DR (2012)
Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
Radiat Oncol, 7, 75
DOI 10.1186/1748-717X-7-75, PubMed 22621752

Ree AH, Kristensen AT, Saelen MG, de Wijn R, Edvardsen H, Jovanovic J, Abrahamsen TW, Dueland S, Flatmark K (2012)
Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancer
PLoS One, 7 (11), e50806
DOI 10.1371/journal.pone.0050806, PubMed 23226389

Heck SL, Gulati G, Ree AH, Schulz-Menger J, Gravdehaug B, Røsjø H, Steine K, Bratland A, Hoffmann P, Geisler J, Omland T (2012)
Rationale and design of the prevention of cardiac dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial
Cardiology, 123 (4), 240-7
DOI 10.1159/000343622, PubMed 23207160

Hjortland GO, Meza-Zepeda LA, Beiske K, Ree AH, Tveito S, Hoifodt H, Bohler PJ, Hole KH, Myklebost O, Fodstad O, Smeland S, Hovig E (2011)
Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma
BMC Cancer, 11, 455
DOI 10.1186/1471-2407-11-455, PubMed 22014070

Saelen MG, Flatmark K, Folkvord S, de Wijn R, Rasmussen H, Fodstad Ø, Ree AH (2011)
Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic dissemination
Angiogenesis, 14 (4), 481-9
DOI 10.1007/s10456-011-9231-3, PubMed 21833622

Røe K, Kakar M, Seierstad T, Ree AH, Olsen DR (2011)
Early prediction of response to radiotherapy and androgen-deprivation therapy in prostate cancer by repeated functional MRI: a preclinical study
Radiat Oncol, 6, 65
DOI 10.1186/1748-717X-6-65, PubMed 21651782

Bratland A, Dueland S, Hollywood D, Flatmark K, Ree AH (2011)
Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy
Radiat Oncol, 6, 33
DOI 10.1186/1748-717X-6-33, PubMed 21473790

Røe K, Aleksandersen TB, Kristian A, Nilsen LB, Seierstad T, Qu H, Ree AH, Olsen DR, Malinen E (2010)
Preclinical dynamic 18F-FDG PET - tumor characterization and radiotherapy response assessment by kinetic compartment analysis
Acta Oncol, 49 (7), 914-21
DOI 10.3109/0284186X.2010.498831, PubMed 20831478

Røe K, Seierstad T, Kristian A, Mikalsen LT, Mælandsmo GM, van der Kogel AJ, Ree AH, Olsen DR (2010)
Longitudinal magnetic resonance imaging-based assessment of vascular changes and radiation response in androgen-sensitive prostate carcinoma xenografts under androgen-exposed and androgen-deprived conditions
Neoplasia, 12 (10), 818-25
DOI 10.1593/neo.10484, PubMed 20927320

Folkvord S, Flatmark K, Dueland S, de Wijn R, Grøholt KK, Hole KH, Nesland JM, Ruijtenbeek R, Boender PJ, Johansen M, Giercksky KE, Ree AH (2010)
Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling
Int J Radiat Oncol Biol Phys, 78 (2), 555-62
DOI 10.1016/j.ijrobp.2010.04.036, PubMed 20675069

Ree AH, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M, Abrahamsen TW, Flatmark K (2010)
Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study
Lancet Oncol, 11 (5), 459-64
DOI 10.1016/S1470-2045(10)70058-9, PubMed 20378407

Bratland A, Vetrhus T, Grøholt KK, Ree AH (2010)
Preoperative radiotherapy in rectal signet-ring cell carcinoma - magnetic resonance imaging and treatment outcome: Report of six cases
Acta Oncol, 49 (1), 42-9
DOI 10.3109/02841860903081897, PubMed 20100143

Seierstad T, Hole KH, Saelen E, Ree AH, Flatmark K, Malinen E (2009)
MR-guided simultaneous integrated boost in preoperative radiotherapy of locally advanced rectal cancer following neoadjuvant chemotherapy
Radiother Oncol, 93 (2), 279-84
DOI 10.1016/j.radonc.2009.08.046, PubMed 19800704

Bergamaschi A, Hjortland GO, Triulzi T, Sørlie T, Johnsen H, Ree AH, Russnes HG, Tronnes S, Maelandsmo GM, Fodstad O, Borresen-Dale AL, Engebraaten O (2009)
Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models
Mol Oncol, 3 (5-6), 469-82
DOI 10.1016/j.molonc.2009.07.003, PubMed 19713161

Folkvord S, Ree AH, Furre T, Halvorsen T, Flatmark K (2009)
Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status
Int J Radiat Oncol Biol Phys, 74 (2), 546-52
DOI 10.1016/j.ijrobp.2009.01.068, PubMed 19427556

Bratland A, Boender PJ, Høifødt HK, Østensen IH, Ruijtenbeek R, Wang MY, Berg JP, Lilleby W, Fodstad Ø, Ree AH (2009)
Osteoblast-induced EGFR/ERBB2 signaling in androgen-sensitive prostate carcinoma cells characterized by multiplex kinase activity profiling
Clin Exp Metastasis, 26 (5), 485-96
DOI 10.1007/s10585-009-9248-9, PubMed 19294521

Ree AH (2008)
Highly proliferative neuroendocrine carcinoma - influence of radiotherapy fractionation on tumor response
Radiat Oncol, 3, 13
DOI 10.1186/1748-717X-3-13, PubMed 18489745

Seierstad T, Røe K, Sitter B, Halgunset J, Flatmark K, Ree AH, Olsen DR, Gribbestad IS, Bathen TF (2008)
Principal component analysis for the comparison of metabolic profiles from human rectal cancer biopsies and colorectal xenografts using high-resolution magic angle spinning 1H magnetic resonance spectroscopy
Mol Cancer, 7, 33
DOI 10.1186/1476-4598-7-33, PubMed 18439252

Folkvord S, Flatmark K, Seierstad T, Røe K, Rasmussen H, Ree AH (2007)
Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?
Radiother Oncol, 86 (3), 428-34
DOI 10.1016/j.radonc.2007.10.012, PubMed 18006097

Paulsen T, Ree AH, Kaern J, Kjaerheim K, Bassarova A, Berner A, Haldorsen T, Tropé C, Nesland JM (2007)
Expression of matrix metalloproteinase-2 in serous borderline ovarian tumors is associated with noninvasive implant formation
Eur J Gynaecol Oncol, 28 (5), 356-63
PubMed 17966213

Dahm AE, Iversen N, Birkenes B, Ree AH, Sandset PM (2006)
Estrogens, selective estrogen receptor modulators, and a selective estrogen receptor down-regulator inhibit endothelial production of tissue factor pathway inhibitor 1
BMC Cardiovasc Disord, 6, 40
DOI 10.1186/1471-2261-6-40, PubMed 17029634

Flatmark K, Nome RV, Folkvord S, Bratland A, Rasmussen H, Ellefsen MS, Fodstad Ø, Ree AH (2006)
Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition
Radiat Oncol, 1, 25
DOI 10.1186/1748-717X-1-25, PubMed 16887021

Ree AH (2006)
A complex case of rectal neuroendocrine carcinoma with terminal delirium
Nat Clin Pract Gastroenterol Hepatol, 3 (7), 408-13; quiz 414
DOI 10.1038/ncpgasthep0525, PubMed 16819503

Ree AH, Stokke T, Bratland A, Patzke S, Nome RV, Folkvord S, Meza-Zepeda LA, Flatmark K, Fodstad O, Andersson Y (2006)
DNA damage responses in cell cycle G2 phase and mitosis--tracking and targeting
Anticancer Res, 26 (3A), 1909-16
PubMed 16827124

Porojnicu AC, Robsahm TE, Ree AH, Moan J (2005)
Season of diagnosis is a prognostic factor in Hodgkin's lymphoma: a possible role of sun-induced vitamin D
Br J Cancer, 93 (5), 571-4
DOI 10.1038/sj.bjc.6602722, PubMed 16136030

Nome RV, Bratland A, Harman G, Fodstad O, Andersson Y, Ree AH (2005)
Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death
Mol Cancer Ther, 4 (8), 1231-8
DOI 10.1158/1535-7163.MCT-04-0304, PubMed 16093439

Lyng H, Landsverk KS, Kristiansen E, DeAngelis PM, Ree AH, Myklebost O, Hovig E, Stokke T (2005)
Response of malignant B lymphocytes to ionizing radiation: gene expression and genotype
Int J Cancer, 115 (6), 935-42
DOI 10.1002/ijc.20962, PubMed 15723354

DeMasters GA, Gupta MS, Jones KR, Cabot M, Wang H, Gennings C, Park M, Bratland A, Ree AH, Gewirtz DA (2004)
Potentiation of cell killing by fractionated radiation and suppression of proliferative recovery in MCF-7 breast tumor cells by the Vitamin D3 analog EB 1089
J Steroid Biochem Mol Biol, 92 (5), 365-74
DOI 10.1016/j.jsbmb.2004.07.011, PubMed 15698541

Ree AH (2004)
[Cell cycle-targeted therapy]
Tidsskr Nor Laegeforen, 124 (19), 2479-82
PubMed 15477884

Ree AH, Bratland A, Nome RV, Stokke T, Fodstad O, Andersson Y (2004)
Inhibitory targeting of checkpoint kinase signaling overrides radiation-induced cell cycle gene regulation: a therapeutic strategy in tumor cell radiosensitization?
Radiother Oncol, 72 (3), 305-10
DOI 10.1016/j.radonc.2004.07.002, PubMed 15450729

Johansson CC, Yndestad A, Enserink JM, Ree AH, Aukrust P, Taskén K (2004)
The epidermal growth factor-like growth factor amphiregulin is strongly induced by the adenosine 3',5'-monophosphate pathway in various cell types
Endocrinology, 145 (11), 5177-84
DOI 10.1210/en.2004-0232, PubMed 15284208

Ree AH, Bratland A, Solberg Landsverk K, Fodstad O (2004)
Ionizing radiation inhibits the PLK cell cycle gene in a G2 checkpoint-dependent manner
Anticancer Res, 24 (2B), 555-62
PubMed 15160994

Ree AH, Bratland A, Nome RV, Stokke T, Fodstad Ø (2003)
Repression of mRNA for the PLK cell cycle gene after DNA damage requires BRCA1
Oncogene, 22 (55), 8952-5
DOI 10.1038/sj.onc.1207000, PubMed 14654792

Bratland A, Ragnhildstveit E, Bjørnland K, Andersen K, Maelandsmo GM, Fodstad O, Saatcioglu F, Ree AH (2003)
The metalloproteinase inhibitor TIMP-2 is down-regulated by androgens in LNCaP prostate carcinoma cells
Clin Exp Metastasis, 20 (6), 541-7
DOI 10.1023/a:1025860214891, PubMed 14598888

Ree AH, Engebraaten O, Hovig E, Fodstad Ø (2002)
Differential display analysis of breast carcinoma cells enriched by immunomagnetic target cell selection: gene expression profiles in bone marrow target cells
Int J Cancer, 97 (1), 28-33
DOI 10.1002/ijc.1564, PubMed 11774240

Ree AH, Bratland A, Kroes RA, Aasheim HC, Flørenes VA, Moskal JR, Fodstad O, Bruland OS, Maelandsmo GM (2002)
Clinical and cell line specific expression profiles of a human gene identified in experimental central nervous system metastases
Anticancer Res, 22 (4), 1949-57
PubMed 12174869

Bjørnland K, Bratland A, Rugnes E, Pettersen S, Johansen HT, Aasen AO, Fodstad Ø, Ree AH, Maelandsmo GM (2001)
Expression of matrix metalloproteinases and the metastasis-associated gene S100A4 in human neuroblastoma and primitive neuroectodermal tumor cells
J Pediatr Surg, 36 (7), 1040-4
DOI 10.1053/jpsu.2001.24735, PubMed 11431772

Glauser R, Rée A, Lundgren A, Gottlow J, Hämmerle CH, Schärer P (2001)
Immediate occlusal loading of Brånemark implants applied in various jawbone regions: a prospective, 1-year clinical study
Clin Implant Dent Relat Res, 3 (4), 204-13
DOI 10.1111/j.1708-8208.2001.tb00142.x, PubMed 11887657

Bratland A, Risberg K, Maelandsmo GM, Gützkow KB, Olsen OE, Moghaddam A, Wang MY, Hansen CM, Blomhoff HK, Berg JP, Fodstad O, Ree AH (2000)
Expression of a novel factor, com1, is regulated by 1,25-dihydroxyvitamin D3 in breast cancer cells
Cancer Res, 60 (19), 5578-83
PubMed 11034106

Ree AH, Pacheco MM, Tvermyr M, Fodstad O, Brentani MM (2000)
Expression of a novel factor, com1, in early tumor progression of breast cancer
Clin Cancer Res, 6 (5), 1778-83
PubMed 10815897

Grønning LM, Wang JE, Ree AH, Haugen TB, Taskén K, Taskén KA (2000)
Regulation of tissue inhibitor of metalloproteinases-1 in rat Sertoli cells: induction by germ cell residual bodies, interleukin-1alpha, and second messengers
Biol Reprod, 62 (4), 1040-6
DOI 10.1095/biolreprod62.4.1040, PubMed 10727275

Røsok O, Pedeutour F, Ree AH, Aasheim HC (1999)
Identification and characterization of TESK2, a novel member of the LIMK/TESK family of protein kinases, predominantly expressed in testis
Genomics, 61 (1), 44-54
DOI 10.1006/geno.1999.5922, PubMed 10512679

Ree AH, Tvermyr M, Engebraaten O, Rooman M, Røsok O, Hovig E, Meza-Zepeda LA, Bruland OS, Fodstad O (1999)
Expression of a novel factor in human breast cancer cells with metastatic potential
Cancer Res, 59 (18), 4675-80
PubMed 10493524

Ree AH, Hansson V, Walaas SI, Eskild W, Taskén KA (1999)
Calcium/phospholipid-dependent protein kinases in rat Sertoli cells: regulation of androgen receptor messenger ribonucleic acid
Biol Reprod, 60 (5), 1257-62
DOI 10.1095/biolreprod60.5.1257, PubMed 10208993

Ståhl S, Odeberg J, Larsson M, Røsok O, Ree AH, Lundeberg J (1999)
Solid-phase differential display and bacterial expression systems in selection and functional analysis of cDNAs
Methods Enzymol, 303, 495-511
DOI 10.1016/s0076-6879(99)03030-x, PubMed 10349662

Ree AH, Bjørnland K, Brünner N, Johansen HT, Pedersen KB, Aasen AO, Fodstad O (1998)
Regulation of tissue-degrading factors and in vitro invasiveness in progression of breast cancer cells
Clin Exp Metastasis, 16 (3), 205-15
DOI 10.1023/a:1006584624061, PubMed 9568638

Bjørnland K, Lehne G, Johansen HT, Fodstad O, Rugstad HE, Aasen AO, Ree AH (1998)
Human hepatoma cells rich in P-glycoprotein display enhanced in vitro invasive properties compared to P-glycoprotein-poor hepatoma cells
Oncol Res, 10 (5), 255-62
PubMed 9802060

Ree AH, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM, Fodstad O (1997)
High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases
Clin Cancer Res, 3 (9), 1623-8
PubMed 9815852

Ree AH, Maelandsmo GM, Fodstad O (1996)
Regulation of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in MCF-7 cells: comparison with regulatory mechanisms of pS2 expression
Clin Exp Metastasis, 14 (4), 381-8
DOI 10.1007/BF00123397, PubMed 8878412

Berg JP, Ree AH, Sandvik JA, Taskén K, Landmark BF, Torjesen PA, Haug E (1994)
1,25-dihydroxyvitamin D3 alters the effect of cAMP in thyroid cells by increasing the regulatory subunit type II beta of the cAMP-dependent protein kinase
J Biol Chem, 269 (51), 32233-8
PubMed 7798223

Berg JP, Sandvik JA, Ree AH, Sørnes G, Bjøro T, Torjesen PA, Gordeladze JO, Haug E (1994)
1,25-Dihydroxyvitamin D3 attenuates adenylyl cyclase activity in rat thyroid cells: reduction of thyrotropin receptor number and increase in guanine nucleotide-binding protein Gi-2 alpha
Endocrinology, 135 (2), 595-602
DOI 10.1210/endo.135.2.8033808, PubMed 8033808

Ree AH, Taskén K, Hansson V (1994)
Regulation of glucocorticoid receptor (GR) mRNA and protein levels by phorbol ester in MCF-7 cells. Mechanism of GR mRNA induction and decay
J Steroid Biochem Mol Biol, 48 (1), 23-9
DOI 10.1016/0960-0760(94)90247-x, PubMed 8136303

Ree AH, Knutsen HK, Landmark BF, Eskild W, Hansson V (1992)
Down-regulation of messenger ribonucleic acid (mRNA) for the estrogen receptor (ER) by phorbol ester requires ongoing RNA synthesis but not protein synthesis. Is hormonal control of ER mRNA degradation mediated by an RNA molecule?
Endocrinology, 131 (4), 1810-4
DOI 10.1210/endo.131.4.1382961, PubMed 1382961

Kise NJ, Bergsmark JK, Endreseth BH, Reinertsen KV, Ugelstad TP, Ree AH (1992)
[Living and dying alone. An epidemiological study of deaths outside institutions in Oslo in 1989]
Tidsskr Nor Laegeforen, 112 (5), 616-9
PubMed 1557724

Ree AH, Landmark BF, Walaas SI, Lahooti H, Eikvar L, Eskild W, Hansson V (1991)
Down-regulation of messenger ribonucleic acid and protein levels for estrogen receptors by phorbol ester and calcium in MCF-7 cells
Endocrinology, 129 (1), 339-44
DOI 10.1210/endo-129-1-339, PubMed 2055193

Eskild W, Ree AH, Levy FO, Jahnsen T, Hansson V (1991)
Cellular localization of mRNAs for retinoic acid receptor-alpha, cellular retinol-binding protein, and cellular retinoic acid-binding protein in rat testis: evidence for germ cell-specific mRNAs
Biol Reprod, 44 (1), 53-61
DOI 10.1095/biolreprod44.1.53, PubMed 1849753

Ree AH, Frøysa A, Eskild W, Jahnsen T, Hansson V (1990)
Biphasic regulation of the messenger ribonucleic acid coding for the estrogen receptor by cyclic adenosine 3':5'-monophosphate in tumor Leydig cells
Cancer Res, 50 (5), 1528-31
PubMed 2154326

Ree AH, Landmark BF, Eskild W, Levy FO, Lahooti H, Jahnsen T, Aakvaag A, Hansson V (1989)
Autologous down-regulation of messenger ribonucleic acid and protein levels for estrogen receptors in MCF-7 cells: an inverse correlation to progesterone receptor levels
Endocrinology, 124 (5), 2577-83
DOI 10.1210/endo-124-5-2577, PubMed 2651098

Levy FO, Ree AH, Eikvar L, Govindan MV, Jahnsen T, Hansson V (1989)
Glucocorticoid receptors and glucocorticoid effects in rat Sertoli cells
Endocrinology, 124 (1), 430-6
DOI 10.1210/endo-124-1-430, PubMed 2909375

Review articles

Kalanxhi E, Meltzer S, Ree AH (2020)
Immune-Modulating Effects of Conventional Therapies in Colorectal Cancer
Cancers (Basel), 12 (8)
DOI 10.3390/cancers12082193, PubMed 32781554

Ree AH, Redalen KR (2015)
Personalized radiotherapy: concepts, biomarkers and trial design
Br J Radiol, 88 (1051), 20150009
DOI 10.1259/bjr.20150009, PubMed 25989697

Ree AH, Flatmark K, Saelen MG, Folkvord S, Dueland S, Geisler J, Redalen KR (2015)
Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: opportunities for signaling-adapted therapies
Crit Rev Oncol Hematol, 95 (1), 114-24
DOI 10.1016/j.critrevonc.2015.01.003, PubMed 25624177

Ree AH, Meltzer S, Flatmark K, Dueland S, Kalanxhi E (2014)
Biomarkers of treatment toxicity in combined-modality cancer therapies with radiation and systemic drugs: study design, multiplex methods, molecular networks
Int J Mol Sci, 15 (12), 22835-56
DOI 10.3390/ijms151222835, PubMed 25501337

Pettersen EO, Ebbesen P, Gieling RG, Williams KJ, Dubois L, Lambin P, Ward C, Meehan J, Kunkler IH, Langdon SP, Ree AH, Flatmark K, Lyng H, Calzada MJ, Peso LD, Landazuri MO, Görlach A, Flamm H, Kieninger J, Urban G, Weltin A, Singleton DC, Haider S, Buffa FM, Harris AL et al. (2014)
Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium
J Enzyme Inhib Med Chem, 30 (5), 689-721
DOI 10.3109/14756366.2014.966704, PubMed 25347767

Gulati G, Heck SL, Ree AH, Gravdehaug B, Røsjø H, Steine K, Bratland Å, Hoffmann P, Geisler J, Omland T (2013)
[Cardioprotective treatment during adjuvant cancer therapy]
Tidsskr Nor Laegeforen, 133 (17), 1832-6
DOI 10.4045/tidsskr.12.1514, PubMed 24042297

Ree AH, Hollywood D (2013)
Design and conduct of early-phase radiotherapy trials with targeted therapeutics: lessons from the PRAVO experience
Radiother Oncol, 108 (1), 3-16
DOI 10.1016/j.radonc.2013.06.007, PubMed 23830196

Ree AH, Bratland A, Dueland S (2008)
[Molecular targeted therapy in colorectal cancer]
Tidsskr Nor Laegeforen, 128 (2), 190-3
PubMed 18202731